Kura Oncology Announces Upcoming Presentations at AACR Annual Meeting 2018
April 09, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 09, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Provides Regulatory Update on Tipifarnib and Reports Fourth Quarter and Full Year 2017 Financial Results
March 12, 2018 16:05 ET
|
Kura Oncology, Inc.
– Company plans to initiate registration-directed trial of tipifarnib in second half of 2018 following recent end of Phase 2 meeting with the FDA – – Single-arm trial to enroll at least 59...
Kura Oncology to Present at Cowen and Company 38th Annual Health Care Conference
March 06, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology to Report Fourth Quarter and Full Year 2017 Financial Results
March 05, 2018 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 05, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Provides Update on Phase 2 Trial of Tipifarnib in HRAS Mutant Head and Neck Cancer
February 15, 2018 11:00 ET
|
Kura Oncology, Inc.
– Confirmed partial responses observed in five of six evaluable patients with HRAS mutant HNSCC – – Rate of enrollment increasing with three additional patients enrolled in four months – –...
Kura Oncology to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 08, 2018 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Added to Nasdaq Biotechnology Index
December 18, 2017 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Dec. 18, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...
Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers
December 11, 2017 10:00 ET
|
Kura Oncology, Inc.
CXCR4/CXCR2 expression ratio and bone marrow homing of myeloid cells identified as potential markers for tipifarnib in MDS, AML and CMML CXCL12/CXCR4 pathway a potential therapeutic target of...
Kura Oncology Reports Positive Phase 2 Study of Tipifarnib in Chronic Myelomonocytic Leukemia
December 10, 2017 09:00 ET
|
Kura Oncology, Inc.
– Primary objective met with three objective responses in nine patients with RAS wild-type tumor status (33%), two additional RAS wild-type patients pending best response evaluation – – All nine...
Kura Oncology to Host Investor Day on November 16, 2017
November 09, 2017 16:05 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical-stage biopharmaceutical company focused on the development of precision medicines for oncology, today...